Innovative biopharmaceutical developer integrating R&D, manufacturing and sales of recombinant protein therapeutics and microecological (probiotic) drugs. Targets antiviral, hematology, oncology & immunology, and degenerative disease therapies; key products include recombinant human erythropoietin, recombinant human interferon α1b, recombinant human G‑CSF and a Clostridium butyricum dual‑live probiotic.